Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Dynavax Technologies
DVAX
Dynavax Technologies
Rising Costs And Hurdles Will Threaten Vaccine Sector With Opportunity
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
11 May 25
Updated
23 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$11.10
0.5% overvalued
intrinsic discount
23 Jul
US$11.15
Loading
1Y
10.9%
7D
-0.4%
Author's Valuation
US$11.1
0.5% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$11.1
0.5% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-163m
674m
2014
2017
2020
2023
2025
2026
2028
Revenue US$421.3m
Earnings US$117.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
13.49%
Biotech revenue growth rate
10.68%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.90%
Calculation
US$117.88m
Earnings '28
x
10.95x
PE Ratio '28
=
US$1.29b
Market Cap '28
US$1.29b
Market Cap '28
/
96.59m
No. shares '28
=
US$13.36
Share Price '28
US$13.36
Share Price '28
Discounted to 2025 @ 6.60% p.a.
=
US$11.03
Fair Value '25
